EMA validates Gilead’s marketing application for Elvitegravir for treatment of HIV infection
18 June 2012 | By Gilead Sciences
Gilead Sciences announced that its MAA for elvitegravir has been validated by the EMA...
List view / Grid view
18 June 2012 | By Gilead Sciences
Gilead Sciences announced that its MAA for elvitegravir has been validated by the EMA...
11 May 2012 | By Gilead Sciences
Final FDA decision on the Quad anticipated late summer...
10 May 2012 | By Gilead Sciences
Vote to support approval of once-daily oral Truvada®...
8 May 2012 | By Gilead Sciences
Webcast available through Gilead Corporate website...
1 May 2012 | By Gilead Sciences
Gilead Sciences announced that the first patient has been dosed in a Phase 3 clinical trial...
18 April 2012 | By Gilead Sciences
Presentations include first results for lead hepatitis C candidate GS-7977 in treatment-naïve genotype 1 patients...
7 March 2012 | By Gilead Sciences Inc
Quad currently under review for marketing approval...
17 February 2012 | By Gilead Sciences
Viral relapse seen post treatment with GS-7977 plus ribavirin...
13 February 2012 | By Gilead Sciences Inc
The U.S. FDA has granted a six-month Priority Review for once-daily Truvada®...
18 January 2012 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the U.S. FDA has approved Viread®...
18 January 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that Roy D. Baynes, MD, PhD, will join the company...
17 January 2012 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced the completion to acquire Pharmasset, Inc...
12 January 2012 | By Gilead Sciences
Following the merger, Pharmasset will become a wholly-owned subsidiary of Gilead...
6 January 2012 | By Gilead Sciences
Gilead Sciences, Inc. has received early termination of the required waiting period...
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...